Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals
| Current Price | ₹416.80 |
|---|---|
| Market Cap | ₹67,454 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | 147.8 |
| Return on Equity | 1.15% |
| 52-Week Range | ₹327.60 – ₹440.40 |
| Beta (1Y) | 0.14 |
| Dividend Yield | 0.12% |
1. Generics-18.7% 2. Biosimilars-61.6% 3. Contract Research, Development and Manufacturing Organisation (CRDMO)-22.1%
Biocon Limited is trading at ₹416.80, with a market capitalisation of ₹67,454 Cr.
Biocon Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Biocon Limited has a P/E of 147.8 and a return on equity of 1.15%.